Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

PHARMACEUTICALS

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

SOMATOSTATIN IMPURITY F CRS (0.01 MG)

SOMATOSTATIN IMPURITY F CRS (0.01 MG)

ND

DISCOVER
PHENOXYBENZAMINE HYDROCHLORIDE CRS (80 MG)

PHENOXYBENZAMINE HYDROCHLORIDE CRS (80 MG)

ND

DISCOVER
PHENOXYBENZAMINE IMPURITY B CRS (10 MG)

PHENOXYBENZAMINE IMPURITY B CRS (10 MG)

ND

DISCOVER
PHENOXYBENZAMINE FOR SYSTEM SUITABILITY CRS (10 MG)

PHENOXYBENZAMINE FOR SYSTEM SUITABILITY CRS (10 MG)

ND

DISCOVER
CROSCARMELLOSE SODIUM CRS (20MG)

CROSCARMELLOSE SODIUM CRS (20MG)

ND

DISCOVER
TERAZOSIN FOR SYSTEM SUITABILITY A CRS (0.59 MG)

TERAZOSIN FOR SYSTEM SUITABILITY A CRS (0.59 MG)

ND

DISCOVER
4-DODECYLRESORCINOL CRS (80 MG)

4-DODECYLRESORCINOL CRS (80 MG)

ND

DISCOVER
CHELERYTHRINE CHLORIDE CRS (25 MG)

CHELERYTHRINE CHLORIDE CRS (25 MG)

ND

DISCOVER
DIPOTASSIUM CLORAZEPATE MONOHYDRATE - REFERENCE SPECTRUM (N/

DIPOTASSIUM CLORAZEPATE MONOHYDRATE - REFERENCE SPECTRUM (N/

ND

DISCOVER
CHENODEOXYCHOLIC ACID FOR SYSTEM SUITABILITY CRS (50 MG)

CHENODEOXYCHOLIC ACID FOR SYSTEM SUITABILITY CRS (50 MG)

ND

DISCOVER
CHENODEOXYCHOLIC ACID FOR PEAK IDENTIFICATION CRS (50 MG)

CHENODEOXYCHOLIC ACID FOR PEAK IDENTIFICATION CRS (50 MG)

ND

DISCOVER
CICLOSPORIN FOR SYSTEM SUITABILITY A CRS (1 MG)

CICLOSPORIN FOR SYSTEM SUITABILITY A CRS (1 MG)

ND

DISCOVER